Skip to the content
VYNE Therapeutics
Rooted in Innovation
  • About Us
    • About VYNE™
    • Our Mission
    • Who We Are
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Responsibility
  • Pipeline
    • Pipeline Overview
    • FMX114 Program
    • InhiBET™ BET Inhibitor Platform
    • VYN201
    • VYN202
  • Careers
  • Investors & Media
    • Investor Overview
    • Stock Information
    • Press Releases
    • Events & Presentations
    • ES&G / Culture
    • Corporate Governance
    • Filings & Financials
  • Contact Us
Search
Menu
Close search
Close
  • About Us
    • About VYNE™
    • Our Mission
    • Who We Are
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Responsibility
  • Pipeline
    • Pipeline Overview
    • FMX114 Program
    • InhiBET™ BET Inhibitor Platform
    • VYN201
    • VYN202
  • Careers
  • Investors & Media
    • Investor Overview
    • Stock Information
    • Press Releases
    • Events & Presentations
    • ES&G / Culture
    • Corporate Governance
    • Filings & Financials
  • Contact Us

SEC Filing: Form 8-K

March, 20 2019

Current report

  • Post date March 20, 2019
Read More

Nothing left to load.

About Us

  • About VYNE™
  • Our Mission
  • Who We Are
  • Leadership
  • Board of Directors
  • Scientific Advisory Board
  • Corporate Responsibility
  • Contact Us

Pipeline

  • Pipeline Overview
  • FMX114
  • InhiBET™ BET Inhibitor Platform
  • VYN201
  • VYN202

Investors

  • Investor Overview
  • Stock Information
  • Press Releases
  • Events & Presentations
  • Investors & Media
  • ES&G / Culture
  • Corporate Governance
  • Filings & Financials

Careers

  • Job Openings
  • Our Mission
  • Terms of Use
  • Privacy Policy
  • Compliance
  • Site Map

© 2022 Vyne Therapeutics Inc. All Rights Reserved

You Are Leaving VYNETherapeutics.com

Return to
VYNE Therapeutics
Continue to
Amzeeq.com

You Are Leaving VYNETherapeutics.com

Return to
VYNE Therapeutics
Continue to
Zilxi.com